INS and type 2 diabetes mellitus: Efsitora's phase 2 program included 3 treat-to-target studies: 1 study in patients withT2D previously treated with once-daily basal insulin (127), 1 in insulin-naive patients with T2D, and 1 in patientswith T1D (128).